Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Brain Malignancies Clear all
Completed Not applicable Interventional Results available

Smartphone App to Improve Physical Activity in Older Adults With MCI/Mild Dementia

NCT04950998
View directory record Official record
Conditions
Sedentary Lifestyle, Dementia, Mild, Mild Cognitive Impairment, Memory and Thinking Problems
Interventions
Moving Up - A
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
65 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 17, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

NCT00544284
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, temozolomide, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 17, 2026, 5:02 AM EDT
Terminated Phase 1 Interventional

Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors

NCT01902771
View directory record Official record
Conditions
Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme, High Grade Glioma
Interventions
Dendritic Cell Vaccine, Tumor Lysate, Imiquimod, Leukapheresis
Biological · Other · Procedure
Lead sponsor
Edward Ziga
Other
Eligibility
1 Year to 29 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 17, 2026, 5:02 AM EDT
Completed No phase listed Observational

Neurofibromatosis Type 1 Brain Tumor Genetic Risk

NCT01707836
View directory record Official record
Conditions
Neurofibromatosis Type 1, Pediatric Brain Tumor
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 18 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 17, 2026, 5:02 AM EDT
Withdrawn No phase listed Observational

Monitoring Neural Tissues Properties by Modulated Imaging (MI)

NCT00555711
View directory record Official record
Conditions
Brain Tumor
Interventions
Modulated Imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
1 Minute and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 17, 2026, 5:02 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome

NCT01425944
View directory record Official record
Conditions
Sturge-Weber Syndrome
Interventions
Not listed
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
1 Month and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
7
States / cities
Baltimore, Maryland • Detroit, Michigan • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 17, 2026, 5:02 AM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 17, 2026, 5:02 AM EDT
Terminated No phase listed Observational

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

NCT02095353
View directory record Official record
Conditions
Central Nervous System Neoplasms
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 17, 2026, 5:02 AM EDT
Terminated Phase 1Phase 2 Interventional

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

NCT03904862
View directory record Official record
Conditions
Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma
Interventions
CX 4945
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 17, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

NCT00979862
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 17, 2026, 5:02 AM EDT
Not listed Phase 4 Interventional

Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions

NCT02478346
View directory record Official record
Conditions
Cerebrovascular Disorders, Intracranial Neoplasms
Interventions
Fluorescein Sodium
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Sep 17, 2026, 5:02 AM EDT
Completed Not applicable Interventional Results available

Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial

NCT05860127
View directory record Official record
Conditions
Dementia, Cognitive Impairment, Mild, Dementia, Vascular, Dementia, Mixed, Dementia With Lewy Bodies, Dementia Frontal, Dementia Moderate, Dementia of Alzheimer Type, Dementia, Mild
Interventions
Referral for Cognitive Stimulation Therapy, No change to Standard of Care
Behavioral · Other
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Farmington, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 17, 2026, 5:02 AM EDT
Completed No phase listed Observational

PET/CT Imaging of Malignant Brain Tumors With 124I-NM404

NCT01516905
View directory record Official record
Conditions
Glioblastoma, Brain Metastases
Interventions
NM404
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 17, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

NCT00002754
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
Interventions
monoclonal antibody Me1-14 F(ab')2
Biological
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 17, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

NCT01250470
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Mixed Glioma, Recurrent Brain Neoplasm
Interventions
Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim
Other · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 17, 2026, 5:02 AM EDT
Terminated Not applicable Interventional

Feasibility of the LUM Imaging System for Detection of Cancer to the Brain

NCT03717142
View directory record Official record
Conditions
Low Grade Glioma of Brain, Glioblastoma, Metastasis to Brain
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 17, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

NCT01730950
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
bevacizumab, radiation therapy
Biological · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Walnut Creek, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Sep 17, 2026, 5:02 AM EDT
Terminated No phase listed Observational

Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects

NCT01018927
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Administering three additional MRI images
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 17, 2026, 5:02 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab Deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 17, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

NCT02885324
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Malignant Brain Tumor, High Grade Glioma
Interventions
Cabozantinib
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 17, 2026, 5:02 AM EDT
Recruiting No phase listed Observational

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742
View directory record Official record
Conditions
Fabry Disease
Interventions
Not listed
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2034
U.S. locations
92
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 17, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00643097
View directory record Official record
Conditions
Malignant Neoplasms of Brain
Interventions
PEP-3 vaccine, sargramostim, Temozolomide
Biological · Drug
Lead sponsor
John Sampson
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 17, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer

NCT00052286
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Fatigue
Interventions
modafinil
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 17, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

G207 Followed by Radiation Therapy in Malignant Glioma

NCT00157703
View directory record Official record
Conditions
Malignant Glioma
Interventions
G207
Drug
Lead sponsor
MediGene
Industry
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 15, 2008 · Synced Sep 17, 2026, 5:02 AM EDT